E
180 Life Sciences Corp.
ATNF
$2.00
$0.010.50%
E
Sell
3/14/2023Downgrade
180 Life Sciences Corp. (ATNF) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index.
180 Life Sciences Corp. (ATNF) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index.
D
Sell
2/3/2023Upgraded
180 Life Sciences Corp. (ATNF) was upgraded to D- from E+ on 2/3/2023 due to an increase in the valuation index.
180 Life Sciences Corp. (ATNF) was upgraded to D- from E+ on 2/3/2023 due to an increase in the valuation index.
E
Sell
1/19/2023Downgrade
180 Life Sciences Corp. (ATNF) was downgraded to E+ from D- on 1/19/2023 due to a decline in the valuation index and volatility index.
180 Life Sciences Corp. (ATNF) was downgraded to E+ from D- on 1/19/2023 due to a decline in the valuation index and volatility index.
D
Sell
1/4/2023Upgraded
180 Life Sciences Corp. (ATNF) was upgraded to D- from E+ on 1/4/2023 due to an increase in the valuation index.
180 Life Sciences Corp. (ATNF) was upgraded to D- from E+ on 1/4/2023 due to an increase in the valuation index.
E
Sell
12/19/2022Downgrade
180 Life Sciences Corp. (ATNF) was downgraded to E+ from D- on 12/19/2022 due to a decline in the valuation index, volatility index and total return index.
180 Life Sciences Corp. (ATNF) was downgraded to E+ from D- on 12/19/2022 due to a decline in the valuation index, volatility index and total return index.
D
Sell
11/23/2022Downgrade
180 Life Sciences Corp. (ATNF) was downgraded to D- from D on 11/23/2022 due to a significant decline in the valuation index, efficiency index and solvency index. Net income declined 831.02% from $2.94M to -$21.49M, and total capital declined 39.35% from $43.72M to $26.51M.
180 Life Sciences Corp. (ATNF) was downgraded to D- from D on 11/23/2022 due to a significant decline in the valuation index, efficiency index and solvency index. Net income declined 831.02% from $2.94M to -$21.49M, and total capital declined 39.35% from $43.72M to $26.51M.
D
Sell
8/15/2022Upgraded
180 Life Sciences Corp. (ATNF) was upgraded to D from D- on 8/15/2022 due to a significant increase in the valuation index, efficiency index and solvency index. Net income increased 87.97% from $1.56M to $2.94M, the quick ratio increased from 0.38 to 0.53, and debt to equity declined from 0.03 to 0.02.
180 Life Sciences Corp. (ATNF) was upgraded to D from D- on 8/15/2022 due to a significant increase in the valuation index, efficiency index and solvency index. Net income increased 87.97% from $1.56M to $2.94M, the quick ratio increased from 0.38 to 0.53, and debt to equity declined from 0.03 to 0.02.
D
Sell
7/13/2022Downgrade
180 Life Sciences Corp. (ATNF) was downgraded to D- from D on 7/13/2022 due to a decline in the volatility index.
180 Life Sciences Corp. (ATNF) was downgraded to D- from D on 7/13/2022 due to a decline in the volatility index.
D
Sell
6/27/2022Upgraded
180 Life Sciences Corp. (ATNF) was upgraded to D from D- on 6/27/2022 due to an increase in the total return index and valuation index.
180 Life Sciences Corp. (ATNF) was upgraded to D from D- on 6/27/2022 due to an increase in the total return index and valuation index.
D
Sell
6/10/2022Downgrade
180 Life Sciences Corp. (ATNF) was downgraded to D- from D on 6/10/2022 due to a decline in the volatility index, total return index and valuation index.
180 Life Sciences Corp. (ATNF) was downgraded to D- from D on 6/10/2022 due to a decline in the volatility index, total return index and valuation index.
D
Sell
5/25/2022Upgraded
180 Life Sciences Corp. (ATNF) was upgraded to D from D- on 5/25/2022 due to an increase in the volatility index.
180 Life Sciences Corp. (ATNF) was upgraded to D from D- on 5/25/2022 due to an increase in the volatility index.
D
Sell
5/23/2022Upgraded
180 Life Sciences Corp. (ATNF) was upgraded to D- from E+ on 5/23/2022 due to a major increase in the growth index and solvency index. Operating cash flow increased 58.77% from -$5.03M to -$2.07M, earnings per share increased from $0.03 to $0.0459, and debt to equity declined from 0.05 to 0.03.
180 Life Sciences Corp. (ATNF) was upgraded to D- from E+ on 5/23/2022 due to a major increase in the growth index and solvency index. Operating cash flow increased 58.77% from -$5.03M to -$2.07M, earnings per share increased from $0.03 to $0.0459, and debt to equity declined from 0.05 to 0.03.
E
Sell
4/18/2022Downgrade
180 Life Sciences Corp. (ATNF) was downgraded to E+ from D on 4/18/2022 due to a substantial decline in the growth index and total return index. Earnings per share declined from $0.2317 to $0.03, operating cash flow declined 25.6% from -$4M to -$5.03M, and EBIT declined 5.8% from -$4.22M to -$4.46M.
180 Life Sciences Corp. (ATNF) was downgraded to E+ from D on 4/18/2022 due to a substantial decline in the growth index and total return index. Earnings per share declined from $0.2317 to $0.03, operating cash flow declined 25.6% from -$4M to -$5.03M, and EBIT declined 5.8% from -$4.22M to -$4.46M.
D
Sell
11/17/2021Upgraded
180 Life Sciences Corp. (ATNF) was upgraded to D from E+ on 11/17/2021 due to a major increase in the growth index, solvency index and valuation index. The quick ratio increased from 0.04 to 0.48, earnings per share increased from -$0.75 to $0.5386, and debt to equity declined from 0.58 to 0.01.
180 Life Sciences Corp. (ATNF) was upgraded to D from E+ on 11/17/2021 due to a major increase in the growth index, solvency index and valuation index. The quick ratio increased from 0.04 to 0.48, earnings per share increased from -$0.75 to $0.5386, and debt to equity declined from 0.58 to 0.01.
E
Sell
11/8/2021Downgrade
180 Life Sciences Corp. (ATNF) was downgraded to E+ from D- on 11/8/2021 due to a major decline in the total return index, volatility index and efficiency index. Total capital declined 82.45% from $24.52M to $4.3M, and net income declined 44.82% from -$16.2M to -$23.46M.
180 Life Sciences Corp. (ATNF) was downgraded to E+ from D- on 11/8/2021 due to a major decline in the total return index, volatility index and efficiency index. Total capital declined 82.45% from $24.52M to $4.3M, and net income declined 44.82% from -$16.2M to -$23.46M.
D
Sell
8/2/2021Upgraded
180 Life Sciences Corp. (ATNF) was upgraded to D- from E on 8/2/2021 due to a large increase in the solvency index and efficiency index. The quick ratio increased from 0.14 to 0.19, and debt to equity declined from 0.12 to 0.08.
180 Life Sciences Corp. (ATNF) was upgraded to D- from E on 8/2/2021 due to a large increase in the solvency index and efficiency index. The quick ratio increased from 0.14 to 0.19, and debt to equity declined from 0.12 to 0.08.
E
Sell
5/3/2021Upgraded
180 Life Sciences Corp. (ATNF) was upgraded to E from E- on 5/3/2021 due to a substantial increase in the total return index.
180 Life Sciences Corp. (ATNF) was upgraded to E from E- on 5/3/2021 due to a substantial increase in the total return index.
E
Sell
2/4/2021None
180 Life Sciences Corp. (ATNF) was downgraded to E- from U on 02/04/2021.
180 Life Sciences Corp. (ATNF) was downgraded to E- from U on 02/04/2021.
NASDAQ
05/02/2024 3:48PM Eastern
Quotes delayed
